Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Liabilities from Discontinued Operations: 2023-2024

  • Cidara Therapeutics' Liabilities from Discontinued Operations was N/A to $11,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $11,000, marking a year-over-year change of. This contributed to the annual value of $24.7 million for FY2023, which is N/A change from last year.
  • As of Q2 2024, Cidara Therapeutics' Liabilities from Discontinued Operations stood at $11,000, which was down 99.96% from $24.7 million recorded in Q4 2023.
  • In the past 5 years, Cidara Therapeutics' Liabilities from Discontinued Operations ranged from a high of $24.7 million in Q4 2023 and a low of $11,000 during Q2 2024.
  • For the 2-year period, Cidara Therapeutics' Liabilities from Discontinued Operations averaged around $12.3 million, with its median value being $12.3 million (2023).